Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GUSB | P08236 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6404875 | 0.85 | ADORA2B (0.46) | GAAADORA2BALDH1A1MAPTGUSB | |
| SCHEMBL4648207 | 0.81 | USP2 (0.46) | GAAALDH1A1ALOX15HSD17B10 | |
| SCHEMBL6406082 | 0.77 | GAA (0.68) | GAAADORA2BALDH1A1RAB9ACREBBP | |
| SCHEMBL6409001 | 0.76 | ADORA2B (0.53) | GAAADORA2BALDH1A1MAPTTSHR | |
| SCHEMBL6407610 | 0.74 | ADORA2B (0.49) | GAAADORA2BALDH1A1MAPTGUSB | |
| SCHEMBL6406084 | 0.72 | RAB9A (0.48) | GAAADORA2BALDH1A1RAB9ACREBBP | |
| SCHEMBL4649479 | 0.72 | GAA (0.54) | GAAADORA2BALDH1A1RAB9ACREBBP | |
| SCHEMBL6404869 | 0.71 | GAA (0.56) | GAAADORA2BALDH1A1RAB9ACREBBP | |
| SCHEMBL4744658 | 0.70 | GAA (0.66) | GAAADORA2BALDH1A1RAB9AALOX15 | |
| SCHEMBL4649301 | 0.70 | GAA (0.70) | GAAADORA2BALDH1A1RAB9ACREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050282838-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2005-12-22 | — | — | US | claimed |
| US-20050282838-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282838-A1 | Compounds, compositions, and methods | PCNA, MKI67, TP53 | GAA 349/4885ADORA2B 3513/4885ALDH1A1 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.